Although, as described above, different KRAS mutations show a preference for activating different downstream signaling, hyperactivation of the mitogen-activated protein kinase (MAPK) pathway is generally recognized as a key feature in KRAS-driven lung cancer cells. The gene discussed is KRAS; the disease is lung carcinoma.